N

NextCure
D

NXTC

1.17700
USD
-0.03
(-2.73%)
Market Closed
Volume
2,178
EPS
-2
Div Yield
-
P/E
-1
Market Cap
32,963,867
OverviewSignalsIdeasNews
Related Instruments
    C
    CHKP
    -3.390
    (-1.91%)
    174.280 USD
    CRWD
    CRWD
    -7.64
    (-2.22%)
    336.77 USD
    F
    FFIV
    -3.660
    (-1.51%)
    238.410 USD
    FTNT
    FTNT
    -0.270
    (-0.29%)
    94.200 USD
    PANW
    PANW
    -7.58
    (-1.92%)
    396.32 USD
    P
    PFPT
    0
    (0%)
    0.000000 USD
    Q
    QLYS
    -3.930
    (-2.63%)
    145.590 USD
    S
    SPLK
    0
    (0%)
    0.000000 USD
    V
    VRNT
    -1.230
    (-4.98%)
    23.460 USD
    ZS
    ZS
    -7.160
    (-3.43%)
    201.390 USD
    More
News

Title: NextCure

Sector: Healthcare
Industry: Biotechnology
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.